BPC-157
Body Protection Compound 157, pentadecapeptide BPC 157, PL 14736, PL-10, PLD-116
BPC-157 is a synthetic 15-amino-acid peptide said to derive from a larger protein in human gastric juice. It has an unusually large animal literature showing accelerated healing of tendon, muscle, ligament, bone and gut tissue, and almost no human evidence at all. It is not an approved medicine anywhere and is prohibited in competitive sport.
Explained on the blog
This page is the reference record. For the story behind it, read:
Mechanism
BPC-157 has no identified receptor. After more than thirty years of research nobody has shown what it binds to, and its effects are described instead as a convergence of downstream changes. The most consistent of these are angiogenic and nitric-oxide-related: in endothelial cells it upregulates VEGFR2 and promotes VEGFR2-Akt-eNOS signalling, and in whole-animal work it counteracts both the vasoconstriction produced by NOS inhibition with L-NAME and the excess vasodilation produced by L-arginine, which is why the originating group describes it as balancing the NO system rather than driving it. In tendon fibroblasts it increases growth hormone receptor expression at both mRNA and protein level, and it promotes fibroblast outgrowth, survival and migration through the FAK-paxillin pathway. It also blunts pro-inflammatory cytokine output and protects gastrointestinal mucosa against NSAID and alcohol injury.
Two caveats belong in any honest mechanistic account. First, the claim that BPC-157 is a natural fragment of a gastric protein has never been confirmed by an independent laboratory: the parent protein has not been isolated, sequenced or deposited in any protein database. The peptide is best understood as a synthetic sequence of uncertain natural provenance. Second, the mechanistic literature is dominated by one research group in Zagreb and its collaborators. That does not make the findings wrong, but it means the usual safeguard of independent replication is largely absent.
What the research shows
The animal literature is genuinely large and internally consistent. Rodent models show improved functional, structural and biomechanical outcomes across transected Achilles tendon, quadriceps muscle, medial collateral ligament, segmental bone defects, colocutaneous and other fistulas, NSAID-induced enteropathy, and several central nervous system injury models. Chang and colleagues provided two of the most-cited mechanistic anchors: accelerated tendon fibroblast outgrowth and migration in 2011, and upregulation of the growth hormone receptor in 2014.
The human record is close to empty, and this is the single most important fact about the compound. The 2025 HSS Journal systematic review searched from database inception to 3 June 2024 and found exactly one clinical study among 36 included papers: a retrospective series in which 7 of 12 patients given an intra-articular injection for unspecified chronic knee pain reported relief lasting more than six months. Its authors stated plainly that no clinical safety data were found. The underlying paper (Lee and Padgett, 2021) contacted 16 patients: 11 of the 12 given BPC-157 alone and 3 of the 4 given it with thymosin beta-4 reported significant improvement, with no control group, no randomisation and no standardised outcome measure. Two other small uncontrolled human reports exist: a 2024 pilot in which 10 of 12 women with interstitial cystitis reported complete resolution after a single injection, and a two-participant intravenous infusion pilot published in 2025, which is an anecdote rather than a trial. A 2026 review in Pharmaceutics put the entire published human evidence at fewer than 30 subjects across three uncontrolled pilot studies, none using standardised pharmaceutical preparations, and noted that no phase 2 trial has been completed. Pliva, a Croatian pharmaceutical company, developed the peptide as PL 14736 and ran early-phase work in ulcerative colitis around 2000 to 2005; the Zagreb group repeatedly refers to it as safe in those trials, but no efficacy or safety report from that programme has ever appeared in the peer-reviewed literature, and the assertion circulates only as a parenthesis inside review articles. A registered Phase 2 trial in acute hamstring muscle strain, NCT07437547, is listed as recruiting with a planned enrolment of 120 and a start date of 2 February 2026, comparing pentadecapeptide BPC 157 against placebo; verified against the ClinicalTrials.gov registry, it would be the first properly designed and registered efficacy study in humans. No results have been posted.
Evidence assessment
Preclinical only
The 2025 HSS Journal systematic review screened 544 articles and included 36, of which 35 were preclinical and the single clinical item was a retrospective series of 12 patients; the widely repeated claim that BPC-157 was 'safe in clinical trials' for inflammatory bowel disease traces to assertions inside review articles, not to any published trial report.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review Limited evidence
Preclinical models showed improved musculoskeletal healing, but the only clinical evidence was a retrospective series in which 7 of 12 patients reported relief beyond six months, and the authors state no clinical safety data were found.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration Preclinical only
BPC-157 increased tendon fibroblast outgrowth, survival and migration, with activation of the FAK-paxillin pathway.
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts Preclinical only
Growth hormone receptor was among the most upregulated genes, increasing at both mRNA and protein level in a dose- and time-dependent way.
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Preclinical only
Summarises the animal wound-healing literature across skin, gut, tendon, muscle and bone.
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response Preclinical only
Confirms the sequence GEPPPGKPADDAGLV and molecular weight 1419, and asserts in passing that the peptide was safe in inflammatory bowel disease trials.
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Limited evidence
No measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers and no side effects reported in two participants.
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Limited evidence
11 of 12 patients given BPC-157 alone and 3 of 4 given it with thymosin beta-4 reported significant improvement in knee pain; outcomes were self-reported and uncontrolled.
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Limited evidence
10 of 12 reported complete resolution of symptoms and 2 reported around 80% improvement, with no adverse events recorded; there was no control group.
BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers Preclinical only
Put the published human evidence at fewer than 30 subjects across three uncontrolled pilot studies, none using standardised pharmaceutical preparations, and noted that no phase 2 trial has been completed.
Safety
There is no adequately powered human safety data of any kind. Preclinical toxicity work from the originating group reports no adverse effects across organ systems and no established LD50, but this has not been independently replicated to regulatory standards. Three concerns deserve stating. BPC-157 is a potent angiogenic agent in animals, and the effect of chronic systemic angiogenic stimulation on occult or subclinical tumours has never been studied; this is a theoretical risk, not a documented one, but it is unexamined rather than excluded. Almost all material available to consumers is manufactured outside pharmaceutical GMP, and independent analyses of research-grade peptides have repeatedly found incorrect peptide content, truncated sequences, residual synthesis solvents and bacterial endotoxin. Finally, injection carries the ordinary infection and injury risks of any non-sterile parenteral procedure performed outside clinical supervision.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. It is not an authorised medicine, not a licensed food supplement and not a permitted cosmetic ingredient. Supplied or promoted for human use it falls within the definition of a medicinal product under the Human Medicines Regulations 2012, making such sale unlawful. |
| United States | Not approved by the FDA for any indication and never submitted for approval. Placed on the FDA's interim 503A Category 2 list in September 2023, a designation for bulk substances presenting significant safety risks in compounding. FDA subsequently removed a group of peptides from that list after their nominations were withdrawn and referred peptide nominations to the Pharmacy Compounding Advisory Committee; removal from Category 2 reflects a procedural withdrawal, not approval or any finding of safety. Sold widely online labelled 'for research use only'. At the Pharmacy Compounding Advisory Committee meeting of 23 July 2026, FDA's briefing described BPC-157 as not well characterised, found no evidence of effectiveness for the nominated use (ulcerative colitis) and insufficient clinical safety information, and recommended against adding it to the 503A bulks list. News reports put the committee's non-binding vote at 8 to 6, with one abstention, in favour of inclusion; FDA had not announced a decision as of September 2026. |
| WADA (sport) | Prohibited at all times under S0, non-approved substances. Athletes subject to testing should treat it as banned in and out of competition. |
Questions
No. BPC-157 has never been approved by the FDA, the EMA or the MHRA for any indication, and no marketing application has ever been submitted. It was placed on the FDA's 503A Category 2 list of bulk substances presenting significant safety risks for compounding in September 2023. That list has since been revised for procedural reasons, which is sometimes reported online as though the FDA changed its assessment. It did not.
Barely. The published human evidence is fewer than 30 people across three small uncontrolled studies: a retrospective knee pain series of 16 patients, a pilot of 12 women with interstitial cystitis, and a two-person intravenous safety pilot. None had a control group. Early trials in ulcerative colitis were run by Pliva in the early 2000s but were never published, so their results cannot be checked. A Phase 2 hamstring strain trial, NCT07437547, is registered as recruiting with a planned 120 participants and a February 2026 start, and would be the first proper efficacy trial in people. No results exist yet.
In practice it functions as a legal shield rather than a description of the buyer. Genuine research reagents are sold to institutions with documented handling controls. The phrase allows sellers to market an unapproved drug to consumers while disclaiming responsibility for what happens next, and it means the product is made outside pharmaceutical GMP with no requirement for sterility, identity, purity or endotoxin testing.
Yes. It is prohibited at all times under category S0 of the WADA Prohibited List, which covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. Athletes should assume it will result in an anti-doping rule violation if detected.